anti-CD30 antibody-drug conjugate SGN-35C

{
  "id": "MLC-T-ONC-010329",
  "term": "anti-CD30 antibody-drug conjugate SGN-35C",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of brentuximab (cAC10), a chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor necrosis factor (TNF) receptor CD30 (tumor necrosis factor receptor superfamily, member 8; TNFRSF8), conjugated to a camptothecin-derived topoisomerase 1 inhibitor (TOP1i), with potential antineoplastic activity. Upon administration, anti-CD30 ADC SGN-35C targets and binds to CD30 expressed on tumor cells. Upon binding and internalization, the TOP1i moiety is released, binds to TOP1 and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of CD30-expressing tumor cells. CD30 may be constitutively expressed in certain B- and T-cell lymphoma while expression is limited in normal, healthy cells.",
  "synonyms": [
    "ADC SGN-35C",
    "anti-CD30 ADC SGN-35C",
    "anti-CD30/TOP1i ADC SGN-35C"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-cd30-antibody-drug-conjugate-sgn-35c/"
}